Samsung Biologics to launch $1.8 billion all-cash bid for PolyPeptide
PolyPeptide’s board unanimously backed the offer as Samsung Biologics seeks peptide drug capabilities and plans to delist the Swiss company after closing.
- On Monday, South Korean firm Samsung Biologics announced an all-cash tender offer to acquire Swiss contract manufacturer PolyPeptide Group for 1.46 billion Swiss francs .
- Seeking to address rising demand for GLP-1 obesity and diabetes treatments, Samsung Biologics intends to integrate PolyPeptide's specialized peptide expertise and global manufacturing network across Europe, the U.S., and India.
- PolyPeptide's board unanimously recommended the offer at 44.31 Swiss francs per share, representing a 6.1% premium over Friday's closing price; Draupnir Holding, the company's largest shareholder, agreed to tender its 55.65% stake.
- Samsung Biologics plans to launch the formal tender offer by late August, aiming to close the transaction by year-end; following completion, the company intends to delist PolyPeptide from the SIX Swiss Exchange as a wholly owned subsidiary.
- Combining these scientific strengths, the transaction aims to establish Samsung Biologics as a leading global multi-modality CDMO by merging its existing antibody manufacturing capabilities with PolyPeptide's peptide-based active pharmaceutical ingredients.
56 Articles
56 Articles
The South Korean giant Samsung Biologics wants to take over Baar peptide manufacturer Polypeptides. The example shows that Asian companies are pursuing ambitious growth plans in the production of medicines.
The South Korean Samsung Biologics will launch a cash offer of 1.46 billion Swiss francs (US$ 1.81 billion) by the Swiss manufacturer of medicines under contract PolyPeptide, informed the two companies in separate communiqués. Material exclusive to subscribers. To have full access, access the link of the material and make your registration.
![[your]NEWS](/_next/image?url=https%3A%2F%2Fgroundnews.b-cdn.net%2Finterests%2Ffb6dc495f74049f513563c33352175eaa0ecd509.jpg%3Fwidth%3D24&w=64&q=75){kind=small}
Samsung Biologics to Acquire Swiss Drugmaker PolyPeptide in $1.81 Billion Deal to Expand Peptide Medicine Business
South Korea's Samsung Biologics has announced plans to acquire Swiss contract drug manufacturer PolyPeptide in an all-cash transaction valued at approximately 1.46 billion Swiss francs, or about $1.81 billion. The acquisition marks another major step in Samsung Biologics' global expansion strategy and significantly strengthens its position in the rapidly growing market for peptide-based medicines, including treatments for obesity, diabetes, and …
The South Korean pharmaceutical group offers shareholders 44.31 Swiss francs per share in cash.
Samsung Biologics Acquires Swiss Company Specializing in Obesity Drugs for 2.7 Trillion Won; Largest Domestic Bio M&A Deal. Samsung Biologics is investing 2.7 trillion won to acquire a Swiss contract development and manufacturing organization (CDMO) specializing in peptides. The company is shifting its business focus from antibody drugs to peptides, the core substances for obesity and diabetes treatments.
Coverage Details
Bias Distribution
- 68% of the sources are Center
![[your]NEWS](/_next/image?url=https%3A%2F%2Fgroundnews.b-cdn.net%2Finterests%2Ffb6dc495f74049f513563c33352175eaa0ecd509.jpg%3Fwidth%3D60&w=128&q=75)
Factuality
To view factuality data please Upgrade to Premium
